Skip to main navigation Skip to search Skip to main content

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

  • Shivaani Kummar*
  • , Martin E. Gutierrez
  • , Erin R. Gardner
  • , Xiaohong Chen
  • , William D. Figg
  • , Maria Zajac-Kaye
  • , Min Chen
  • , Seth M. Steinberg
  • , Christine A. Muir
  • , Mary Ann Yancey
  • , Yvonne R. Horneffer
  • , Lamin Juwara
  • , Giovanni Melillo
  • , S. Percy Ivy
  • , Maria Merino
  • , Len Neckers
  • , Patricia S. Steeg
  • , Barbara A. Conley
  • , Giuseppe Giaccone
  • , James H. Doroshow
    • Anthony J. Murgo
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

106 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science